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Although CD8+ T cells help controlMycobacterium tuberculosis infection, theirM. tuberculosisAg repertoire, in vivo frequency, and
functionality in human tuberculosis (TB) remains largely undefined. We have performed genome-based bioinformatics searches to
identify new M. tuberculosis epitopes presented by major HLA class I supertypes A2, A3, and B7 (covering 80% of the human
population). A total of 432M. tuberculosis peptides predicted to bind to HLA-A*0201, HLA-A*0301, and HLA-B*0702 (represent-
ing the above supertypes) were synthesized andHLA-binding affinities determined. Peptide-specific CD8+ T cell proliferation assays
(CFSE dilution) in 41 M. tuberculosis-responsive donors identified 70 new M. tuberculosis epitopes. Using HLA/peptide tetramers
for the 18 most prominently recognized HLA-A*0201-binding M. tuberculosis peptides, recognition by cured TB patients’ CD8+
T cells was validated for all 18 epitopes. Intracellular cytokine staining for IFN-g, IL-2, and TNF-a revealed mono-, dual-, as well as
triple-positive CD8+ T cells, indicating these M. tuberculosis peptide-specific CD8+ T cells were (poly)functional. Moreover, these
T cells were primed during natural infection, because they were absent fromM. tuberculosis-noninfected individuals. Control CMV
peptide/HLA-A*0201 tetramers stained CD8+ T cells inM. tuberculosis-infected and noninfected individuals equally, whereas Ebola
peptide/HLA-A*0201 tetramers were negative. In conclusion, the M. tuberculosis-epitope/Ag repertoire for human CD8+ T cells is
much broader than hitherto suspected, and the newly identifiedM. tuberculosisAgs are recognized by (poly)functional CD8+ T cells
during control of infection. These results impact on TB-vaccine design and biomarker identification. The Journal of Immunology,
2011, 186: 1068–1080.
O
ne third of the world’s population is latently infected
with Mycobacterium tuberculosis, and each year, 1.8
million people die of tuberculosis (TB) (1, 2). Bacillus
Calmette-Gue´rin (BCG) vaccination has been used for almost
a century, but its protective efficacy is highly variable and in-
complete, especially against pulmonary TB, the main and conta-
gious form of the disease. BCG’s effect wanes in adolescents, and
revaccination does not confer additional protection. Currently, the
TB problem is aggravated by HIV coinfection, and the emer-
gence of multidrug-resistant and extensively drug-resistant M.
tuberculosis strains, which threaten to set back TB control to the
preantibiotic era (3, 4). New and better vaccines against TB are
urgently needed, but to be able to develop these, a radically im-
proved understanding of what constitutes protective host immu-
nity is warranted. It is well established that CD4+ T cell responses
play a major role in acquired immunity against M. tuberculosis
(5–7). There is, however, mounting evidence that CD8+ T cells are
also involved in the control of M. tuberculosis infection and
in mediating optimal host defense in small animal models, non-
human primates, and human infection (8–14).
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Following recognition of mycobacterial Ags on infected cells,
CD8+ T cells contribute to M. tuberculosis control through: 1)
IFN-g and TNF-a production (9, 15–17); 2) lysis of infected
host cells (16–18); and 3) direct killing of mycobacteria (19–21).
One study demonstrated clonal CD4+ and CD8+ T cell expansion
in granulomas from subjects with latent TB infection (22), and
similar changes in the TCR repertoire were reported in peripheral
blood versus pleural fluid in TB patients (23). Furthermore, CD8+
T cells specific for a number of mycobacterial Ags have been
isolated from human and mouse models, consistent with the hy-
pothesis that CD8+ T cells are constantly being stimulated with
Ag (18, 20). One of us reported that the frequency of M. tuber-
culosis Ag85A-specific CD8+ T cells correlated with therapy-
induced curative responses in children: Ag85A epitope-specific
CD8+ T cells during active TB produced low levels of IFN-g and
perforin, which normalized after therapy (24). In a later study, we
reported similar findings for CD8+ T cells directed against six M.
tuberculosis epitopes (two of which were newly identified). In
that study, it was also found that M. tuberculosis peptide-specific
IL-2+/IFN-g+ CD8+ T cell responses were associated with natural
protection against developing TB disease (15). In parallel studies,
Kaufmann and colleagues (25) found clonal expansion of effec-
tor memory CD8+ T cells in older children with TB, with po-
tential impact on the course and severity of disease. Lewinsohn
and colleagues (26) reported clonally expanded CD8+ T cells that
recognized a number of M. tuberculosis epitopes in the context
of HLA-A and -B alleles, and we ourselves reported Ag85A, B,
and C epitopes activating human CD8+ T cells (13, 14, 27, 28).
Despite these studies, little remains known about the size, qua-
lity, and specificity of M. tuberculosis-specific CD8+ MHC-Ia–
restricted T cell responses in TB patients (20) and their relevance
to control of infection (i.e., prevention of progression to TB
disease).
The complete genome sequence of M. tuberculosis encodes
3985 coding open reading frames (ORFs) (29). Surprisingly, M.
tuberculosis-specific epitopes have been identified in only 270
ORFs, representing only 7% of the M. tuberculosis genome. In
fact, 30 ORFs account for 65% of all epitopes reported (30). This
indicates that our current knowledge of the M. tuberculosis
antigenome/epitome is limited and incomplete and that many
more relevant M. tuberculosis Ags and epitopes likely remain to
be discovered, particularly for CD8+ T cells (20). The search for
Ags that stimulate human CD8+ T cells requires new search
strategies, because classical protein expression technologies are
not easily amenable to unravel CD8+ T cell responses. Recently
developed new and powerful bioinformatics prediction tools may
help to identify candidate epitopes and thus minimize the labori-
ous screening of peptides for immunobiological characteristics of
Ags capable of eliciting a protective immune response.
Using novel bioinformatics search tools in combination with
functional immunological screening strategies, we have selected
new M. tuberculosis proteins, which were likely to contain CD8+
T cell-stimulating HLA class Ia-restricted epitopes (reverse Ag
discovery). We also used unbiased forward Ag discovery, in which
expression libraries representing the whole M. tuberculosis ge-
nome were screened for proteins that are targets for B cell re-
sponses in TB patients. Within the selected proteins, potential
peptide epitopes were identified that were restricted by any three
of the major HLA class Ia supertypes (A2, A3, and B7), which
cover .80% of individuals from different ethnic groups (31).
These predicted epitopes were validated using specific tetramers and
peptide stimulation combined with intracellular cytokine staining
(ICS) to quantify polyfunctional CD8+ T cell responses in cured TB
patients and immune donors.
Materials and Methods
Study subjects
Buffy coats from 41 in vitro purified protein derivative (PPD)-responsive
(average IFN-g responses to PPD: 1828 pg/ml, range 101 to .5000 pg/
ml), HLA-typed, healthy anonymous blood bank donors (Sanquin, Leiden,
The Netherlands) were used for the study. Their HLA class I types and
their responses to PPD and ESAT6/CFP10 are shown in the Supplemental
Table I. No clinical information is available for these donors other than that
they were healthy and had no chronic viral infections or other contra-
indications for donating blood. BCG in The Netherlands is only admin-
istered to people at risk for TB exposure, and the TB incidence in The
Netherlands is extremely low, such that the vast majority of our donors
(.95%) is highly unlikely to have been vaccinated with BCG or to have
had exposure to M. tuberculosis. All individuals gave written consent
before blood donation. The study was approved by the Institutional Review
Board of the Leiden University Medical Center.
In the second phase of the study, peripheral blood was obtained from 10
HLA-A*0201–positive adults with recently cured TB disease (six males,
four females; age range 46–67 y) from the Dipartimento di Medicina
Clinica e delle Patologie Emergenti, University Hospital, Palermo, Italy,
and 10 tuberculin (PPD)-negative healthy subjects (seven males and three
females, age range, 32–51 y). The cured TB patients had had clinical and
radiological findings consistent with active pulmonary TB. Diagnosis had
been confirmed by bacteriological isolation of M. tuberculosis and by
clinical and radiological features. All patients had been treated in accor-
dance with Italian guidelines and had received multidrug therapy for 6 mo.
TB treatment was successful in all participants as evidenced by the ab-
sence of any clinical or radiographic evidence of active disease, the con-
firmed completion of anti-TB chemotherapy, and sterile mycobacterial
cultures. Blood samples were taken at time points well after cessation of
treatment. None of the cured TB patients had been vaccinated during in-
fancy with BCG, had evidence of HIV infection, or was being treated with
steroid or other immunosuppressive or anti-TB drugs at the time of their
sampling. Tuberculin (PPD) skin tests were considered positive when the
induration diameter was larger than 5 mm at 72 h since injection of 1 U
PPD (Statens Serum Institute, Copenhagen, Denmark). All Italian subjects
were HLA typed serologically, whereas the HLA-type A*0201 was con-
firmed to be A*0201 using sequence-specific oligonucleotide primers.
All individuals gave written consent before blood donation. The study
was approved by the Ethical Committee of the Dipartimento di Medicina
Clinica e delle Patologie Emergenti, University Hospital, Palermo. The 10
healthy controls had no symptoms or signs of active TB nor had they been
vaccinated with BCG. They were tuberculin skin test negative as well as
in vitro QuantiFERON-TB Gold test (QFT-G; Cellestis, Victoria, Australia)
negative.
Bioinformatics strategy to identify CD8+ T cell epitopes
Complete sequenced genome of M. tuberculosis strain H37Rv (National
Center for Biotechnology Information [NCBI] Refseq Id: NC_000962)
were retrieved from GenBank (http://www.ncbi.nlm.nih.gov/Genbank/).
All 3918 candidate protein-encoding genomic sequences were submitted to
the SubCell 1.0 (http://www.cbs.dtu.dk/services/SubCell/) and prediction
performed using the option “gram positive bacteria” in the server. The
SubCell server generated a list of 370 secreted proteins (the predic-
tion program, SignalP, predicted 340 proteins with a signal peptide [the
classical secretion pathway], SecretomeP predicted 10 proteins for the
nonclassical secretion pathway, and lastly, TATP predicted 20 proteins to
have a twin-Arg signal peptide cleavage site characteristic for bacteria).
NetCTL 1.0 server (http://www.cbs.dtu.dk/services/NetCTL-1.0/) was used
for predicting 9-mer CD8+ T cell epitopes in M. tuberculosis protein
sequences. Briefly, this method integrates prediction of MHC binding,
proteasomal C-terminal cleavage and TAP transport efficiency (32). Pre-
diction was performed for three main HLA supertypes: HLA-A2, -A3, and
-B7. A threshold cutoff value of 0.42 in NetMHC corresponding to a pre-
dicted binding affinity of ,500 nM was used.
Epitope selection criteria
Epitopes were selected using eight different selection criteria from proteins
that were selected based on suspected immunogenicity. In bold below, the
protein selections are shown; the numbers in parentheses represent the
number of potential epitopes selected for further study within each protein
group. A total of 498 peptides were selected initially but due to difficulties
in peptide synthesis or purification, 66 peptides were either cancelled or
discarded, leaving 432 peptides. A full list of proteins, which have been used
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for the peptide prediction for each selection, is provided in Supplemental
Table II.
TB-vaccine Ags (n = 27). This group contains candidate epitopes from
proteins being evaluated in TB-vaccine trials. These proteins were selected
because they have been relatively well studied and are known to be immu-
nogenic. The following proteins were used for the prediction: M. tuber-
culosis72f (Rv0125—NP_214639.1 [protein accession number according to
NCBI] and Rv1196—[YP_177795.1]), TB10.4 (Rv0288—NP_214802.1),
HBHA (Rv0475—NP_214989.1), Ag85B (Rv1186c—NP_216402.1),
HspX (Rv2031c—NP_216547.1), Ag85A (Rv3804c—NP_218321.1), and
ESAT-6 (Rv3875—YP_178023.1).
M. tuberculosis CD8+ T cell epitope-expressing Ags (n = 60). This group
contains candidate epitopes from proteins with already known CD8 T cell
epitopes (33). This selection is included because proteins containing im-
munogenic CD8 T cell epitopes have been reported to be enriched in other
CD8 T cell epitopes in HIV (33).
Best predicted M. tuberculosis epitopes (n = 59). This group contains
candidate epitopes with the highest combined NetCTL score based on
peptide MHC binding, proteasomal C-terminal cleavage, and TAP transport
efficiency.
Conserved candidate Ags (n = 65). This group contains candidate epitopes
that are conserved among related or closely related organisms. One rationale
to include this selection is that heterologous immunity may exist to cross-
reactive epitopes in other organisms or strains of the same organism (re-
viewed in Ref. 34). Furthermore, there is a general belief that vaccines may
be more effective if they focus on Ags that are under functional or struc-
tural constraints, as variation in these regions may affect the fitness of the
pathogen. The best predicted peptides are 100% conserved in the following
bacterial strains (NCBI Refseq Id in parentheses): M. tuberculosis
CDC1551 (NC_002755), M. bovis AF2122/97 (NC_002945), M. leprae TN
(NC_002677), M. avium subsp. paratuberculosis str. k10 (NC_002944), Co-
rynebacterium glutamicum ATCC 13032 (NC_006958), C. efficiens YS-314
(NC_004369), C. glutamicum ATCC 13032 (NC_003450), C. diphtheriae
NCTC 13129 (NC_002935), Streptomyces coelicolor A3(2) (NC_003888),
S. avermitilis MA-4680 (NC_003155), and Nocardia farcinica IFM 10152
(NC_006361).
M. tuberculosis DosR regulon-encoded latency Ags (n = 63). This group
contains the best-predicted candidate epitopes from a list of recently dis-
covered immunogenic proteins from theM. tuberculosis DosR regulon (28,
35). This selection was included because Ags of this dormancy regulon
may contribute to the control of latent M. tuberculosis infection (28).
Proteins with B cell epitopes (n = 52). This group contains candidate
epitopes predicted from novel proteins with B cell epitopes discovered by
generation of shotgun expression library (U. Sahin and A. Zaigler, un-
published observations). Sera from TB patient blood samples were used for
immunoscreening. This particular selection was included because proteins
containing B cell epitopes are likely also to host T cell epitopes (e.g., see
Ref. 36).
Secreted M. tuberculosis Ags (n = 59). This group contains candidate
epitopes from potentially secreted M. tuberculosis Ags, because these are
considered to be immunodominant and involved in protective immunity.
Secreted proteins are readily available for Ag processing and presentation
by MHC class I molecules on the infected host cell (37). Selection of
peptides was based on a list of known secreted proteins obtained from the
TubercuList database (http://genolist.pasteur.fr/TubercuList/).
Hypothetical proteins predicted to be secreted (n = 47). This group con-
tains candidate epitopes from unknown hypothetical proteins predicted to
be secreted by both including proteins using the classical [with an NH2
terminal signal peptide (38)] and nonclassical secretion pathway (39).
A prediction server, SubCell version 1.0, was used to predict various types
of signal peptides and subcellular location in Gram-negative and Gram-
positive bacteria (http://www.cbs.dtu.dk/services/SubCell; see above). Se-
creted proteins were then selected for M. tuberculosis.
Peptides and biochemical peptide-HLA class I binding assay
The 9-mer peptides were synthesized by standard 9-fluorenylmethylox-
ycarbonyl chemistry (Mimotope; Shafer-N, Copenhagen, Denmark). Pep-
tides were distributed at 20 mg/vial and stored lyophilized at 220˚C until
use (for more details, see Ref. 32). Peptides were dissolved just before use.
The biochemical peptide-HLA class I binding assay was performed as
previously described (40).
Isolation of PBMCs
PBMC were isolated from buffy coats by density gradient centrifugation
using Ficoll (Pharmacy, Leiden University Medical Center) and Leucosep
tubes (Greiner, The Netherlands). Freshly isolated PBMC were cryopre-
served for later use.
Proliferation assay
Proliferation was measured using CFSE dilution and flow cytometry. PBMC
from study subjects were thawed, washed, and labeled with CFSE (Mo-
lecular Probes, Leiden, The Netherlands) at a final concentration of 5 mM
for 10 min at 37˚C. Washed, counted, and viable cells were seeded in six
replicates in 96-well round-bottom plates at a concentration of 2 3 105
in the presence of control Ags (PPD, 5 mg/ml [Statens Serum Institute,
Copenhagen, Denmark]), PHA 2 mg/ml (Remel; Oxoid, Haarlem, The
Netherlands), or the test peptides (final concentration 10 mg/ml). Culture
medium used was IMDM with glutamax supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin (Invitrogen, Breda, The Netherlands),
and 10% pooled human serum. After 7 d of incubation at 37˚C in a 5%
CO2 humidified incubator, cells were harvested and stained for further
analysis on the flow cytometer.
Flow cytometry for CFSE assay
Cells were stained for 30 min at 4˚C using anti–CD8-allophycocyanin
(DakoCytomation, Heverlee, Belgium), anti–CD3-PerCP, and anti–CD4-
PE (BD Biosciences). Cells were then washed in PBS 0.1% BSA (Sigma-
Aldrich, Zwijndrecht, The Netherlands), fixed in 1% paraformaldehyde
(Pharmacy, Leiden University Medical Center) and analyzed on an LSRII
with an HTS plate loader (BD Biosciences). Analysis was done using
FACSDiva software (BD Biosciences). Cells gated on live lymphocytes
combined with gating on CD3+CD8+ T cells were analyzed for CFSE
proliferation. The D geometric mean was used as a measure of proliferation
and calculated as follows: D geometric mean = geometric mean (non-
proliferated cells) 2 geometric mean (total cells) (see Supplemental Fig. 1
for explanation). The D geometric mean was then used to calculate the
relative proliferation that is the percentage of the maximal proliferation
(PHA) corrected for spontaneous proliferation (medium): ([D geometric
mean sample 2 D geometric mean control medium]/[D geometric mean
PHA 2 D geometric mean control medium]) 3 100% = percentage of
maximal proliferation. The cutoff value for a positive proliferative response
was arbitrarily set at 10% relative proliferation.
Tetramer staining
Tetramers were generated using a “one-pot, mix-and-read” strategy re-
cently published by us (41) Tetramer staining was carried out as described
in detail previously (15). PBMC (106/ml) were incubated in U-bottom 96-
well plates, washed twice in PBS containing 1% FCS (Sigma-Aldrich), and
stained for 30 min at 4˚C with PE-labeled tetramers (35 ml each), washed,
subsequently stained with FITC-labeled anti-CD8 mAb (clone HIT8a; BD
Biosciences), and analyzed by flow cytometry on an FACSCalibur. Data
were analyzed with the use of FlowJo software (Tree Star, Ashland, OR).
Viable lymphocytes were gated by forward and side scatter, and the an-
alysis was performed on 100,000 acquired CD8 events for each sample. A
cutoff of 0.01% was used as described previously (15); values below this
were set to zero.
Intracellular cytokine staining
ICS was carried out as described in detail previously (15). PBMC (106/ml)
were stimulated with peptides (1 mg/ml, final concentration) in the pres-
ence of monensin for 6 h at 37˚C in 5% CO2. The cells were harvested,
washed, and stained with PerCP Cy5-conjugated anti-CD8 mAb (BD Bio-
sciences) in incubation buffer (PBS-1% FCS-0.1% Na azide) for 30 min at
4˚C. The cells were washed twice in PBS-1% FCS and fixed with PBS-4%
paraformaldehyde overnight at 4˚C. Fixation was followed by per-
meabilization with PBS-1% FCS-0.3% saponin-0.1% Na azide for 15 min
at 4˚C. Staining of intracellular cytokines was performed by incubation of
fixed permeabilized cells with PE-labeled anti–IFN-g (clone B27), FITC-
labeled IL-2 Ab (clone MQ1-17H12), and allophycocyanin-labeled anti–
TNF-a (MAb11) or an isotype-matched control mAb (all from BD Bio-
sciences). Cells were acquired and analyzed by FACS as described above.
Analysis was performed on a minimum of 100,000 acquired CD8 events
for each sample.
Negative controls were background staining obtained with PBMC in-
cubated with medium, in the absence of any stimulant or with control
peptide, or similar experiments using PBMC of PPD nonresponsive donors.
Cutoff values for a positive response were predetermined to be in excess of
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0.01% responsive cells. Results below this value were considered negative
and set to zero.
Statistics
Nonparametric Mann–Whitney U test was used to determine statistical
differences in the distribution of the results. The p values ,0.05 were
considered significant. Data were analyzed using statistical software
SYSTAT 11 (Systat Software). The significance of a difference between
two proportions was calculated as described by Armitage et al. (42).
Results
Selection of M. tuberculosis Ags used for bioinformatics-based
epitope identification
The complete genome sequence of M. tuberculosis strain H37Rv
was retrieved from GenBank for in silico epitope prediction using
NetCTL. Proteins were selected using eight different criteria (as
described in detail in Materials and Methods) to evaluate how
proteins could be selected for epitope discovery. Fig. 1 gives an
overview of the strategy employed.
Binding of predicted epitopes to HLA class Ia molecules
A total of 432 peptides were synthesized and binding to the re-
spective HLA molecule determined as summarized in Table I. A
total of 373 (86%) bound to their respective HLA molecules with
a KD #500 nM, which is a normally accepted threshold for im-
munogenicity (43); 236 (55%) bound with high affinity with a KD
#50 nM. Only 7% of the peptides bound with an affinity ,5000
nM. The fraction of peptides binding to HLA-A2 and -B7 with
high affinity (,50 nM) was significantly higher than for HLA-A3
(p , 0.001).
Immunogenicity of predicted new HLA class I-restricted
M. tuberculosis epitopes
PBMC from HLA-A2–, HLA-A3–, and/or HLA-B7–positive PPD
responsive donors were then screened for possible CD8+ T cell
proliferative responses toward the novel peptides. Ten donors with
the appropriate HLA specificity were tested for each peptide (see
also Supplemental Table III).
The results are summarized in Table II (see also Fig. 1, Sup-
plemental Table III). Peptide-induced CD8+ T cell responses were
scored positive when exceeding 10% relative proliferation in two
or more PPD+ donors (as we have described before; see Ref. 44
and Supplemental Fig. 1). In case there was a relatively high
(ranging between 10 and 20%) response against a given peptide in
only one single donor, the peptide-induced response was repeated
and only included as hit when reproducible in that donor. Ac-
cording to these criteria, a total number of 70 out of the 432 tested
peptides (16%) were found to elicit a CD8+ T cell response (Table
II).
When the results were compared, 34% (44 out of 130) of the
predicted HLA-A2 binding peptides were found capable of elic-
iting a proliferative CD8+ T cell response in HLA-A2+ PPD-
responsive donors compared with 6% (9 out of 140) for HLA-
A3 and 10% (17 out of 163) for HLA-B7. That predicted HLA-A2
binding peptides were more frequently recognized was highly
significant (p , 0.001 in both cases) and likely reflects the more
accurately defined peptide-binding motif for this allele. The dif-
ference between the fractions of predicted HLA-A3 and -B7 bind-
ing peptides recognized was not significant.
High-affinity HLA binding peptides are preferentially
recognized compared with medium- or low-affinity binding
peptides
A total of 19% (46 out of 236) of the peptides binding to an HLA
class Ia molecule with an affinity .50 nM were recognized by
the healthy immune donors (Table I). This fraction is significantly
higher than that for the peptides with a lower binding affinity
(.50 nM; p , 0.02). The CD8+ T cell response frequencies to
these latter peptides were 9% (13 out of 137) for intermediate-
affinity binders, 14% (4 out of 29) for low-affinity binders, and,
FIGURE 1. Schematic representation of study design. The complete
genome sequence of M. tuberculosis strain H37Rv from GenBank was
used for in silico CTL epitope prediction using NetCTL 1.0. M. tubercu-
losis proteins were included based on eight different selection criteria
prior to peptide prediction. The numbers in each selection are given in
parentheses. 1. TB-VAC: proteins used in TB vaccine trials; 2. TB-CD8:
M. tuberculosis proteins with known CD8 T cell epitopes; 3. BestPred:
proteins containing peptides with the best prediction values; 4. Cons:
conserved M. tuberculosis proteins; 5. DOS/LAG: proteins encoded by the
M. tuberculosis DosR regulon; 6. Bepi; 7. Secret: secreted proteins; and 8.
PredSecret: M. tuberculosis proteins predicted to be secreted (see Mate-
rials and Methods for details). Epitope predictions were done for HLA-A2,
A3, and B7. A total of 432 peptides were synthesized, and binding affin-
ities were measured in an in vitro biochemical peptide-HLA class I bind-
ing assay (40). CD8+ T cell proliferative responses were performed using
a CFSE dilution assay on PBMC from PPD+ donors in a flow cytometric
analysis.
Table I. Number of peptides in different intervals of binding affinity (KD) values for M. tuberculosis peptides predicted to bind to three different major
HLA class Ia alleles
HLA
High Binders
(KD # 50 nM)
Intermediate Binders
(50 nM , KD # 500 nM)
Low Binders
(500 nM , KD # 5000 nM)
Low or Nonbinders
(KD . 5000 nM) Total/Supertype
Discarded or
Cancelled
A*0201 105 (33) 15 (5) 2 (1) 8 (5) 130 41
A*0301 18 (1) 82 (4) 20 (3) 19 (1) 139 16
B*0702 112 (12) 40 (4) 7 (0) 3 (1) 163 9
Total 236 (46) 137 (13) 29 (4) 30 (7) 432 66
The number of peptides that gave a positive CD8+ T cell proliferative response are in parentheses.
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somewhat unexpectedly, 23% (7 out of 30) for predicted non-
binders.
Frequency of the recognized peptides for each of the eight
selections
Eight different selection criteria were used to select proteins for
epitope prediction (Fig. 1). The results are shown in Table II. The
highest overall proportional frequencies of CD8+ T cell responses
were found in the sets of proteins used in the TB-vaccine Ags set
(TB-VAC; 26%) as well as in the secreted M. tuberculosis Ag set
(Secret; 25%). Two other broad selection criterions, best predicted
epitopes (BestPred) and conserved candidate Ag (Cons), had the
lowest frequencies of CD8+ T cell responses. BestPred and Cons
together had a significantly lower response rate than the other more
specific protein function-based selections combined (TB-VAC,
M. tuberculosis CD8+ T cell epitope-expressing Ags [TB-CD8],
M. tuberculosis DosR regulon-encoded latency Ags [DOS/LAG],
proteins with B cell epitopes [Bepi], Secret, and hypothetical pro-
teins predicted to be secreted [PredSecret]) (p , 0.01). When ana-
lyzingHLA-A2–associatedepitopesonly,we found that the selections
DOS/LAG,Bepi, Secret, andPredSecret yieldedahigher frequencyof
CD8+ T cell-stimulating epitopes compared with other selections,
such as TB-VAC, TB-CD8, BestPred, and Cons (p, 0.001).
The most frequently recognized HLA-A*0201–restricted peptides
were selected for testing in cured TB patients. The 18 most fre-
quently recognized HLA-A*0201–restricted peptides were chosen
for further studies. First, we selected 13 of the above-defined 44
HLA-A*0201–restricted peptides, namely those that were recog-
nized in two or more donors (arbitrary cutoff was .10% relative
CD8+ T cell proliferation). In addition, we also included five
peptides (B118, C250, C255, B130, and B134) that were recog-
nized in a single donor but with a very high CD8+ T cell response
(.20% relative CD8+ T cell proliferation). The characteristics of
all 18 selected HLA-A*0201–restricted epitopes are summarized
in Table III. Sixteen are among the high-affinity HLA-A*0201
binders (KD #50 nM), the majority having a binding affinity #5
nM (n = 14).
Validation and quantitation of M. tuberculosis peptide-specific
CD8+ T cell responses in cured TB patients using tetramers
Using HLA-A2/peptide tetramers for the 18 most frequently HLA-
A*0201–restricted peptides, direct ex vivo recognition by cured
TB patients’ CD8+ T cells was demonstrated for 16 of the 18
M. tuberculosis epitopes (Figs. 2, 3A). Of particular interest was
that several epitopes were recognized by the majority of the cured
TB patients: pmtb4 (A1) and pmtb15 (B182) were recognized
both by 7 out of 10 cured TB patients, whereas several other
peptides were recognized by a sizeable fraction of the patients as
well. The epitopes studied in this paper thus constitute a signifi-
cant expansion of the known antigenome for CD8+ T cells during
M. tuberculosis infection. In all individuals tested, specificity of
tetramer staining was confirmed by the negative data obtained
using tetramers of an irrelevant specificity (the HLA-A*0201/
Ebola peptide; Fig. 3B), a tetramer of an irrelevant positive con-
trol specificity (the HLA-A*0201/CMV peptide, positive in many
cured TB patients and healthy controls (HC) PBMC; Fig. 3B), as
well as absence of staining among PBMC from normal, uninfected
HLA-A*0201–positive donors using the same M. tuberculosis
tetramers (Supplemental Fig. 2).
Mono-, dual-, and triple-cytokine–producing peptide-specific
CD8+ T cells at the single-cell level in TB
IFN-g, IL-2, and TNF-a are relevant cytokines defining functional
populations of Ag-specific CD4+ and CD8+ T cells (45, 46).T
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Mono-, dual-, and triple-functional CD8+ T cells have been re-
ported (45). The functionality of CD8+ T cells was assessed by
peptide/tetramer analysis in cured TB patients and as control HC
were used. The data are shown in Fig. 4, which is a composite
figure combining tetramer with cytokine expression data.
With the exception of M. tuberculosis peptide pMtb7 (B119)
and pMtb6 (B118), single-, double-, and, in some cases, also triple-
positive CD8+ T cells could be detected in the cured TB patients.
CMV peptide stimulation revealed responses in $60% of the
cured TB patients, whereas the Ebola peptide induced very low if
any responses as expected (all ,0.2%). Of interest, some peptides
induced rather strong responses (.0.3%) in the majority of TB
patients, including pmtb14 (B181) (80% of the patients), pmtb15
(B182) (80%), and pmtb4 (A1) (70%). These were also the pep-
tides that typically gave the strongest tetramer responses, such that
functional and tetramer results for the specific peptides are well in
agreement, as visualized in Fig. 4.
Positive tetramer staining and cytokine expression is an al-
most exclusive property of the cured TB patient group, with, as
expected, mostly negative results in the healthy M. tuberculosis
noninfected group (Figs. 4, 5). Control CMV-peptide/HLA-A2
tetramer CD8+ T cell staining was similarly positive in the M.
tuberculosis-infected and M. tuberculosis noninfected groups,
whereas control Ebola-peptide/HLA-A2 tetramer staining was
invariably negative.
Taken together, these results indicate that the newly identifiedM.
tuberculosis epitopes and Ags are recognized by (poly)functional
CD8+ T cells during (control of) infection in TB. The results also
reveal a strong correlation between the presence of M. tubercu-
losis peptide-tetramer–positive and polyfunctional CD8+ T cells in
natural M. tuberculosis infection in man.
Discussion
Whereas relatively much is known about the mycobacterial Ags
recognized by CD4+ T cells (20), surprisingly little is known about
theM. tuberculosis Ags, which activate human CD8+ T cells in TB.
We applied both forward and reverse Ag discovery approaches
to identify new M. tuberculosis epitopes for human CD8+ T cells.
In this study, we report 70 M. tuberculosis HLA-class Ia-restricted
CD8+ T cell-stimulating epitopes (44 HLA-A*0201, 9 HLA*0301,
and 17 HLA-B*0702), of which 58 are new. The results were
validated by using a panel of 20 HLA-A*0201 tetramers and by
ICS, which revealed mono-, double-, and triple-functional CD8+
T cell responses. There was a strong agreement between tetramer
and cytokine positivity. Positive responses in the validation cohort
were seen only in the cured TB patients, but absent from the
FIGURE 2. Tetramer analysis. Shown in
the upper right quadrant of each FACS plot
are the percentages of tetramer-positive
CD8+ T cells from two cured TB patients
(TB#5 and TB#10) and two HC (HC#2 and
HC#10) for all 18 M. tuberculosis peptide/
HLA-A2 tetramers tested, as well as the
negative control Ebola and the positive
control CMV peptide. Values below 0 are
not shown in the upper right quadrants.
Data was analyzed by flow cytometry on
an FACSCalibur and further analyzed
with the use of the FlowJo software. Vi-
able lymphocytes were gated by forward
and side scatter, and the analysis was per-
formed on $100,000 acquired CD8 events
for each sample.
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healthy non-M. tuberculosis-infected control individuals. In an-
other recent study, we have reported the identification of a set of
novel M. tuberculosis epitopes (.50) that are recognized by hu-
man CD8+ T cells in the context of the nonclassical HLA class Ib
molecule HLA-E (44). Those results and the ones reported in this
study very significantly increase our understanding of the human
immune response to M. tuberculosis by identifying large sets of
CD8+ T cell-recognized M. tuberculosis peptides.
We had expected newly discovered epitope frequencies to be
highest for Ags from the TB vaccine Ag group and the M. tu-
berculosis CD8+ T cell epitope-expressing Ag group, because
these contained highly immunogenic proteins (e.g., from M.
FIGURE 3. Representation of the percentage of
CD8+ T cells staining with each of the selected 18
M. tuberculosis peptide- or control Ebola or CMV
peptide-loaded HLA-A2 tetramers. A, Tetramer
staining data for all 10 HLA A2+ cured TB
patients’ PBMC tested directly ex vivo. In brief,
PBMC were cocultured for 30 min with PE-
labeled tetramers, washed, stained for CD8, and
analyzed on an FACSCalibur. The patient num-
bers, ranging from 1–10, are displayed on the x-
axis, whereas the y-axis displays the percentage of
positive CD8+ T cells stained by the tetramer.
Sixteen of the 18 selected peptides were recog-
nized by one or more cured TB patients. The
negative control Ebola peptide-tetramer was neg-
ative for all donors tested (B), both the cured
TB patients and HC. The positive control CMV
peptide-tetramer was recognized by 6 out of 10
donors in each group (B).
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tuberculosis RD regions or culture filtrate proteins) (47–51) or
proteins containing already known CD8+ T cell epitopes reported
by others (13, 16, 22, 45, 52–58). The known CD8+ T cell epitopes
were not deliberately deselected for, but our selection criteria were
set to select those candidate peptide epitopes with the best pre-
dicted combined score and predicted binding affinity.
According to the Immune Epitope Database (IEDB), as of
October 1, 2010, there were a total of 151 known MHC class I-
FIGURE 4. Tetramer staining and cytokine production by CD8+ T cells upon peptide stimulation. The figure shows the combined tetramer staining and
cytokine expression results for all 10 cured TB patients. On the x-axis, the percentage of tetramer+ CD8+ T cells is plotted on the left side of the figures
(black bars), whereas the cytokine response is shown on the right. The y-axis shows the cured TB patients. For the cytokine production, PBMC from 10
cured HLA-A2+ TB patients were cocultured for 6 h with peptide in the presence of monensin. Following incubation, cell surface staining was performed
for CD8 followed by permeabilization and ICS for IFN-g, IL-2, and TNF-a. The white bars represent the percentage of CD8+ T cells producing only one
cytokine: IFN-g, IL-2, or TNF-a. The light gray bars represent the percentage of double-positive CD8+ T cells (IFN-g+IL-2+, IFN-g+TNF-a+, and IL-2+
TNF-a+ cells). The dark bars represent the percentage of triple-positive CD8+ T cells (IFN-g+IL-2+TNF-a+). The negative control Ebola peptide did not
induce significant responses in any of the patients. The positive control CMV peptide did induce cytokine production and polyfunctional T cells in 6 out of
10 patients. This representation of the combined tetramer staining and cytokine expressions reveals the strong correlation between the presence of tetramer-
positive CD8+ T cells and the presence of polyfunctional CD8+ T cells.
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restricted epitopes ofM. tuberculosis (http://www.immuneepitope.
org/). Ninety-three of these known epitopes were found in humans
and are restricted by 6 different HLA-A and 10 HLA-B alleles.
The majority were HLA-A2–restricted epitopes. Twelve of our
predicted and tested peptides can be found in the IEDB and were
found to be MHC class I-restricted CD8+ T cell epitopes by other
groups while this study was ongoing. These epitopes are high-
lighted in red in the arrayed tables. Four of these peptides (C228,
10853, 10861, and 10882) were confirmed as epitopes for CD8+
T cells in our study, whereas the remaining eight were either not
recognized at all in the study reported in this paper or did not meet
the pre-established criteria for positivity: they only scored positive
in one donor and/or induced ,10% CD8+ T cell proliferation. For
example, the known epitope KLQERLAKL (#C250) was able to
induce a very high response (55% CD8+ T cell proliferation) but
only in 1 of the 10 donors in our experiments. Based on this ex-
ceptionally high response, the #C250 peptide was nevertheless
included for tetramer construction.
We found that a higher fraction (34%) of the predicted HLA-A2
binding M. tuberculosis peptides elicited proliferative CD8+ T cell
responses in HLA-A2+ PPD-responsive donors, when compared
with the peptides predicted to bind to HLA-A3 (6%) and HLA-B7
(10%). There are several possible explanations for this. One is
related to the prediction server used, as NetCTL might have
a poorer performance for HLA-A3 and -B7. It is also possible that
fewer M. tuberculosis peptides are able to bind to these super-
types. However, more likely is that the lower frequency of
HLA-A3–associated peptide hits is due to the larger diversity of
FIGURE 5. Representation of the com-
bined tetramer staining and cytokine expres-
sion results for all cured TB patients and
control individuals. In the table, results for
the cured TB patients are shown in the upper
panel, whereas those for the HC are shown
in the lower panel. The left side shows the
tetramer staining results of each individual
donor with each of the 18 selected M. tu-
berculosis peptide/HLA-A2 tetramer, in-
cluding the two control tetramers. White
boxes, no detectable tetramer+ CD8+ T cells;
light gray boxes, percentage of tetramer+
CD8+ T cells is between 0.05 and 0.10%; and
dark gray boxes, percentage of tetramer+
CD8+ T cells is.0.10%. The right half of the
figure shows the sum of the cytokine re-
sponse. White boxes, no cytokine production
could be measured; light gray boxes, the total
percentage of cytokine+ CD8+ T cells ranges
from 0.05–0.10%; dark gray boxes, the total
percentage of cytokine+ CD8+ T cells ranges
from 0.10–1.00%; and black boxes, the total
percentage of cytokine+ CD8+ T cells is
.1.00%).
The Journal of Immunology 1077
specificities among the alleles within the HLA-A3 supertype.
Several studies have shown that peptides bind in larger numbers
and at higher affinity to alleles of the B locus compared with
alleles of the A and C loci (26, 59, 60). These studies therefore
concluded that Ag presentation to CD8+ T cells is dominated by
B locus alleles. The design of epitope-based vaccines should then
be directed toward HLA-B–presented peptides. Our findings do
not directly support this, given the higher number of responses to
M. tuberculosis peptides predicted to bind to HLA-A2 supertype
molecules. Interestingly, a similar distribution of epitopes re-
stricted by different supertypes was also reported by Pasquetto
et al. (61), who performed a large scale screening for pox-virus
epitopes. In that study, the frequencies were 30, 6, and 21% for
HLA-A2, A3, and B7, respectively.
Determination of the peptide-binding affinities for the respective
supertypes revealed a significant correlation between high-affinity
(,50 nM) peptide/MHC binding and the peptides’ ability to trig-
ger CD8+ T cell responses (Table I). In poxvirus systems, similar
associations were reported (62, 63). Unexpectedly, however, in our
study several of the nonbinding peptides (23%; 7 out of 30) were
able to induce positive CD8+ T cell responses (Table I). This may
be because the cell-free peptide-MHC binding assay might have
failed to capture key characteristics of (low-affinity) peptide/MHC
binding (many other chaperones are involved next to MHC alone)
or that these peptides actually bound to and were presented by
HLA class I molecules other than A2/A3/B7.
We have used HLA-A2/peptide tetramers and peptide-specific
single-cell multicytokine analyses to validate the above findings
for the 18 most prominently recognized newM. tuberculosis HLA-
A2–restricted epitopes. Importantly, direct ex vivo recognition by
cured TB patients’ CD8+ T cells was found for 16 of the 18 M.
tuberculosis epitopes (Figs. 2, 3A). The epitopes studied in this
paper thus constitute a significant expansion of the known anti-
genome for CD8+ T cells during M. tuberculosis infection. Of
particular interest was that several epitopes were recognized by
the majority of the cured TB patients: pmtb4, pmtb15, and pmtb14
were recognized by 70–80% of the cured TB patients, whereas
several other peptides were recognized by a sizeable fraction of
the patients as well. Of additional relevance, the peptides were not
recognized by M. tuberculosis noninfected healthy individuals. In
all individuals tested, specificity of tetramer staining was con-
firmed by lack of binding of irrelevant (Ebola) peptide/tetramers,
whereas an unrelated positive control (CMV) peptide/tetramer
visualized positive CD8+ T cells both in multiple cured TB
patients as well as uninfected HLA-A*0201–positive donors.
These results indicate that several of these M. tuberculosis pep-
tides are highly immunogenic in HLA-A2–positive TB patients.
We do not know why these peptides appear particularly immu-
nodominant, but speculate this is due to preferential processing/
presentation separate from MHC binding affinity, as these peptides
displayed high but not exceptional binding affinity compared
with others.
A final aim of our study was to assess the capability of M. tu-
berculosis-specific CD8+ T cells to produce IFN-g, IL-2, and
TNF-a as an indication of multifunctionality, which has been
proposed as a possible correlate of protective immunity (45).
However, recent work, among others from two of our groups in
this study, reported multifunctional T cells to be associated with
TB disease (64). Regardless, the functionality of CD8+ T cells was
detected using peptide/tetramers, and identical-peptide stimulated
PBMC of the same cured TB patients and controls were studied
to determine fractions of specific CD8+ T cells producing IFN-g,
IL-2, and/or TNF-a at the single-cell level. With very few ex-
ceptions, single-, double-, and, in some cases, also triple-positive
CD8+ T cells could be detected in cured TB patients, but not
controls. In line with the tetramer data, CMV peptide stimulation
revealed responses in $60% of the cured TB patients as well as
controls, whereas the Ebola peptide induced very low if any
responses as expected. Of interest was that some peptides induced
strong responses in the majority of the cured TB patients, in-
cluding pmtb14 (B181) (80% of the patients), pmtb15 (B182)
(80%), and pmtb4 (A1) (70%). These same peptides also showed
the strongest tetramer responses. Thus, multifunctional cytokine
production and tetramer results for the specific M. tuberculosis
peptides are well in agreement (Fig. 4).
Although more extensive phenotyping of M. tuberculosis-
specific IFN-g–, IL-2–, and TNF-a–secreting CD8+ T cells was
beyond the scope of this study, previous studies have identified
a relationship between the function and phenotype of memory
CD4+ T cells and have proposed that the IL-2 only-secreting cells
are typical of central memory T cells that persist after Ag clear-
ance, whereas the IFN-g/IL-2– and IFN-g only-secreting T cells
are typical of effector memory T cells (42).
In conclusion, we have identified 70 M. tuberculosis-specific
CD8+ T cell epitopes in healthy PPD+ individuals. Fifty-eight of
these epitopes were novel and have not previously been described
by others. This is a considerable expansion of the existing list of
known M. tuberculosis CD8+ T cell epitopes in the IEDB. Fur-
thermore, our results indicate that the newly identified epitopes
and Ags are recognized by (poly)functional CD8+ T cells during
(control of) infection in TB. Finally, the results reveal a strong
correlation between the presence of M. tuberculosis peptide-tet-
ramer–positive and polyfunctional CD8+ T cells in natural M.
tuberculosis infection in humans. These results provide a wealth
of new M. tuberculosis Ags that may provide targets for TB
vaccine development, particularly in the view of mounting evi-
dence that CD8 T cells are important in controlling TB. Moreover,
the epitopes we have identified may provide novel tools for
monitoring the specific CD8+ T cell response in TB cohorts,
providing potential novel TB biomarkers, analogous to what we
have reported for a limited set of other CD8+ T cell epitopes in TB
recently (15).
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